Replies to post #151448 on Biotech Values

[bladerunner1717]

jq,

Why do you think Squarer is hyping this drug so much? He generally lists it in front of 614 when speaking of the proprietary pipeline. If there is no clinical data in combo, how can he be talking about "late-stage trials" for it?


Bladerunner